Figure 2 shows the tumor volume change in response to monotherapy (177Lu RIT alone, anti-PD-1 ICB alone) or combination therapy (177Lu RIT + ICB). Unlabeled (“cold”) h8C3 mAb was utilized as control. Two doses of 200 μCi (high) or 100 μCi (low) 177Lu-h8C3 or unlabeled h8C3 were administered on days 10 and 17 (Figure 2a–c). Here, PDCD1 is linked to neoplasm.